Patients
We studied the medical records of all locally advanced and advanced
NSCLC patients treated at the Jiangsu Cancer Hospital between May 2018
and March 2021 and identified patients who received the PD-1 inhibitor
alone or in combination with the chemotherapy and/or the bevacizumab
therapy and screened patients who met one or more of the following
criteria: positive for hepatitis B surface antigen; HCV - RNA positive;
Syphilis antibody positive. All patients included in this study had at
least one measurable disease. This study was approved by the Academic
Ethics Committee of Jiangsu Cancer Hospital.